VAERS Explorer
Back to explore

Report #2831658

Received Mar 17, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
Age unknown
State
NV
Recovered
Unknown
Vaccinated
Mar 10, 2021
Onset
Feb 19, 2025
Days to onset
1442
Hospital days
—

Vaccines (4)

TypeNameManufacturerDoseLotRoute / Site
HPV9HPV (GARDASIL 9)MERCK & CO. INC.3——
HPV9HPV (GARDASIL 9)MERCK & CO. INC.4——
HPV9HPV (GARDASIL 9)MERCK & CO. INC.1——
HPV9HPV (GARDASIL 9)MERCK & CO. INC.2——

Symptoms (2)

Extra dose administeredNo adverse event

Symptom narrative

No adverse effects were reported; extra dose of GARDASIL 9; This spontaneous report was received from a nurse and refers to a 16-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 19-FEB-2025, the patient received an extra dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), at 0.5 mL for prophylaxis, after previously completing the 3 doses series on 10-MAR-2021 (injection site, route of administration, expiration date, and lot # were not reported), (extra dose administered). No adverse effects were reported.